TY - JOUR
T1 - Presence of CXCR4-Using HIV-1 in patients with recently diagnosed infection
T2 - Correlates and evidence for transmission
AU - Chalmet, Kristen
AU - Dauwe, Kenny
AU - Foquet, Lander
AU - Baatz, Franky
AU - Seguin-Devaux, Carole
AU - Van Der Gucht, Bea
AU - Vogelaers, Dirk
AU - Vandekerckhove, Linos
AU - Plum, Jean
AU - Verhofstede, Chris
N1 - Funding Information:
Potential conflicts of interest. L. V. and D. V. received consultancy, speakers bureau, and research funding from Pfizer, GlaxoSmithKline, ViiV Healthcare, Gilead, Bristol–Myers Squibb, Tibotec (J&J), Boehringer, Abbott, and Merck Sharp & Dohme. C. V. received a consultancy from Gilead. All other authors report no potential conflicts.
Funding Information:
Financial support. The AIDS Reference Laboratory of Ghent receives support from the Belgian Ministry of Social Affairs through a fund within the Health Insurance System. L. Vandekerckhove is supported by the Fund for Scientific Research, Belgium.
PY - 2012/1/15
Y1 - 2012/1/15
N2 - Background. The prevalence and correlates of CXCR4-use in recently diagnosed patients and the impact of X4/DM transmission remain largely unknown.Method.Genotypic coreceptor use determination on the baseline sample of 539 recently diagnosed individuals. Correlation of coreceptor use with clinical, viral and epidemiological data and with information on transmission events as obtained through phylogenetic analysis of protease and reverse transcriptase sequences. Results. CXCR4-use was predicted in 12 to 19% of the patients, depending on the interpretative cutoff used. CXCR4-use was correlated with lower CD4 + T cell counts and subtype 01-AE infection. No association with viral load was observed. Seven (11%) of 63 transmission clusters and 4 (31%) of 13 donor-source pairs resulted from X4/DM transmission.Conclusion.The results confirmed the relation between CXCR4-use at diagnosis and low baseline CD4+ T cell counts. Significantly more CXCR4-use was predicted in 01-AE infections, which may impose constraints on the use of CCR5 antagonists in certain regions of the world. Observations from the transmission cluster analysis contradict the hypothesis that R5 viruses are selected at transmission, and support the idea that R5 or X4/DM infections result from a stochastic process.
AB - Background. The prevalence and correlates of CXCR4-use in recently diagnosed patients and the impact of X4/DM transmission remain largely unknown.Method.Genotypic coreceptor use determination on the baseline sample of 539 recently diagnosed individuals. Correlation of coreceptor use with clinical, viral and epidemiological data and with information on transmission events as obtained through phylogenetic analysis of protease and reverse transcriptase sequences. Results. CXCR4-use was predicted in 12 to 19% of the patients, depending on the interpretative cutoff used. CXCR4-use was correlated with lower CD4 + T cell counts and subtype 01-AE infection. No association with viral load was observed. Seven (11%) of 63 transmission clusters and 4 (31%) of 13 donor-source pairs resulted from X4/DM transmission.Conclusion.The results confirmed the relation between CXCR4-use at diagnosis and low baseline CD4+ T cell counts. Significantly more CXCR4-use was predicted in 01-AE infections, which may impose constraints on the use of CCR5 antagonists in certain regions of the world. Observations from the transmission cluster analysis contradict the hypothesis that R5 viruses are selected at transmission, and support the idea that R5 or X4/DM infections result from a stochastic process.
UR - http://www.scopus.com/inward/record.url?scp=84555195622&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/22147802
U2 - 10.1093/infdis/jir714
DO - 10.1093/infdis/jir714
M3 - Article
C2 - 22147802
AN - SCOPUS:84555195622
SN - 0022-1899
VL - 205
SP - 174
EP - 184
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -